agent model), there are prostaglandins analoguesethanol model (Robert, 1979) relationships, NSAIDsacetic acid model (Okabe and Amagase, 2005) relationships, dopamine agonistscysteamine model (Selye and Szabo, 1973) relationships, and H 2 blockerscysteamine model (Selye and Szabo, 1973) relationships
If you are experiencing any of these after your appointment, please contact Drip Theory, PLLC @ 859-479-2264
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
Dosing & Reconstitution Guide Educational guide for reconstitution and daily dosing Standard / Gradual Approach (3 mL = ~6.67 mg/mL total) Route: Subcutaneous injection | Frequency: Once daily For 10-unit (0.10 mL) administrations during Weeks 14, consider using 30- or 50-unit insulin syringes for improved readability
